MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE

References

• Rodriguez C, Van Broeck J, Taminiau B, Delmée M, Daube G. Clostridium difficile infection: early history, diagnosis and molecular strain typing methods. Microb Pathog. 2017;97:59–25. doi:10.1016/j.micpath.2016.05.018. PMID: 27238460.
   Web of Science ®Google Scholar
• Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Koganei K, Kunisaki R, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–353. doi:10.1007/s00535-018-1439-1. PMID: 29429045.
   PubMed Web of Science ®Google Scholar
• D´Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with clostridium difficile infection. World J Gastroenterol. 2017;23:4986–5003. doi:10.3748/wjg.v23.i27.4986. PMID: 28785153.
   PubMed Web of Science ®Google Scholar
• Hourigan SK, Sears CL, Oliva-Hemker M. Clostridium difficile infection in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1020–1025. doi:10.1097/MIB.0000000000000666. PMID: 26689599.
   PubMed Web of Science ®Google Scholar
• Li Y, Qian J, Queener E, Shen B. Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2013;19:397–403. doi:10.1097/MIB.0b013e318280fcb9. PMID: 23328770.
   PubMed Web of Science ®Google Scholar
• Regnault H, Bourrier A, Lalande V, Nion-Larmurier I, Sokol H, Seksik P, Barbut F, Cosnes J, Beaugerie L. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. Dig Liver Dis. 2014;46:1086–1092. doi:10.1016/j.dld.2014.09.003. PMID: 25294795.
   PubMedGoogle Scholar
• Vitikainen K, Haapamäki J, Färkklä M, Anttila VJ, Arkkila P. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study. Scand J Gastroenterol. 2018;53:947–951. doi:10.1080/00365521.2018.1492012. PMID: 30041549.
   PubMed Web of Science ®Google Scholar
• Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM Study. Am J Gastroenterol. 2016;111:1141–1146. doi:10.1038/ajg.2016.187. PMID: 27215924.
   PubMed Web of Science ®Google Scholar
• Rao K, Higgins P. Epidemiology, diagnosis and management of Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1744–1754. doi:10.1097/MIB.0000000000000793. PMID: 27120571.
   PubMed Web of Science ®Google Scholar
• Hall IC, O´Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:309–402. doi:10.1001/archpedi.1935.01970020105010.
   Google Scholar
• George RH, Symonds JM, Dimock F, Brown JD, Arabi Y, Shinagawa N, Keighley MR, Alexander-Willians J, Burdon DW. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978;1:695. doi:10.1136/bmj.1.6114.695. PMID: 630301.
   PubMed Web of Science ®Google Scholar
• George WL, Sutter VL, Goldstein EJ, Ludwig SL, Finegold SM. Aetiology of antimicrobial-agent-associated colitis. Lancet. 1978;1:802–803. doi:10.1016/s0140-6736(78)93001-5. PMID: 85818.
   PubMed Web of Science ®Google Scholar
• Perlmann P, Hammarström S, Lagercrantz R, Campbell D. Auto-antibodies to colon in rats and human ulcerative colitis: cross-reactivity with E. coli 014 antigen. Proc Soc Exptl Biol Med. 1967;125:975. doi:10.3181/00379727-125-32253. PMID: 15938314.
   PubMed Web of Science ®Google Scholar
• LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980;1(8165):381–383. doi:10.1016/s0140-6736(80)90939-3. PMID: 6101841.
   PubMed Web of Science ®Google Scholar
• Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet. 1980;1(8165):383–384. doi:10.1016/s0140-6736(80)90940-x. PMID: 6101842.
   PubMed Web of Science ®Google Scholar
• Barlett JG. Clostridium difficile and inflammatory bowel disease. Gastroenterology. 1981;80(4):863–865. doi:10.1016/0016-5085(81)90154-2.
   PubMed Web of Science ®Google Scholar
• Keighley MR, Youngs D, Johnson M, Allan RN, Burdon DW. Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut. 1982;23:410–414. doi:10.1136/gut.23.5.410. PMID: 7076018.
   PubMed Web of Science ®Google Scholar
• Tvede M, Willumsen L. Clostridium difficile in patients with irritable bowel syndrome and ulcerative colitis. Lancet. 1982;1(8281):1124. doi:10.1016/s0140-6736(82)92305-4. PMID: 6122916.
   PubMed Web of Science ®Google Scholar
• Bolton RP, Read AE. Clostridium difficile in toxin megacolon complicating acute inflammatory bowel disease. Br Med J (Clin Res Ed). 1982;285(6340):475–476. doi:10.1136/BMJ.285.6340.475-a. PMID: 6809132.
   PubMedGoogle Scholar
• Greenfield C, Aguilar-Ramirez JR, Pounder RE, Williams T, Danvers M, Marper SR. Clostridium difficile and inflammatory bowel disease. Gut. 1983;24(8):713–717. doi:10.1136/gut.24.8.713.
   PubMed Web of Science ®Google Scholar
• Gurian L, Klein K, Ward TT. Role of Clostridium difficile and Campylobacter jejuni in relapses of inflammatory bowel diseases. West J Med. 1983;138(3):359–360. PMID:6858121.
   PubMedGoogle Scholar
• Pokorney BH, Nichols TW Jr. Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn´s colitis. Am J Gastroenterol. 1981;76(4):374–376. PMID: 6119900.
   PubMed Web of Science ®Google Scholar
• Browman RA, Riley TV. Routine culturing for Clostridium difficile? Pathology. 1984;16:240–242. doi:10.3109/00313028409068530. PMID: 6514390.
   PubMed Web of Science ®Google Scholar
• Hyams JS, McLaughlin JC. Lack of relationship between Clostridium difficile toxin and inflammatory bowel disease in children. J Clin Gastroenterol. 1985;7(5):387–390. doi:10.1097/00004836-198510000-00003. PMID: 4067226.
   PubMed Web of Science ®Google Scholar
• Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr. 1991;13:39–41. doi:10.1097/00005176-199107000-00007. PMID: 1919950.
   PubMed Web of Science ®Google Scholar
• Kochhar R, Ayygari A, Goenka MK, Dhali GK, Aggarwai R, Mehta SK. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol. 1993;16:26–30. doi:10.1097/00004836-199301000-00008. PMID: 8421140.
   PubMed Web of Science ®Google Scholar
• Tremaine WJ. Inflammatory bowel disease and Clostridium difficile-associated diarrhoea: a growing problem. Clin Gastroenterol Hepatol. 2007;5:310–311. doi:10.1016/j.cgh.2006.12.030.3. PMID: 17368229.
   PubMed Web of Science ®Google Scholar
• Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–351. doi:10.1016/j.cgh.2006.12.028. PMID: 17368234.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Bionion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205–210. doi:10.1136/gut.2007.128231. PMID: 17905821.
   PubMed Web of Science ®Google Scholar
• Zilberbeg MD, Shorr AF, Kollef MH. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J. 2008;27(12):1111–1113. doi:10.1097/inf.0b013e31817eef13. PMID: 19068517.
   PubMed Web of Science ®Google Scholar
• Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(10):1432–1442. doi:10.1002/ibd.20500. PMID: 18484669.
   PubMed Web of Science ®Google Scholar
• DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances on Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis. 2008;21:500–507. doi:10.1097/qco.0b013e32830f9397. PMID: 18725800.
   PubMed Web of Science ®Google Scholar
• Ali S, Tamboli CP. Advances in epidemiology and diagnosis of inflammatory bowel diseases. Curr Gastr Rep. 2008;10(6):576–584. doi:10.1007/s11894-008-0105-9. PMID: 19006614.
   PubMedGoogle Scholar
• Hermens DJ, Miner PB Jr. Exacerbation of ulcerative colitis. Gastroenterology. 1991;101(1):254–262. doi:10.1016/0016-5085(91)90487-6.
   PubMed Web of Science ®Google Scholar
• Torsten T, Gilbert J, Meyer F. Metagenomics -a guide from sampling to data analysis. Microb Inform Exp. 2012;2:3. doi:10.1186/2042-5783-2-3. PMID: 22587947.
   PubMedGoogle Scholar
• Bajer L, Kuerka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, Brezina J, Wohl P, Spicak J, Drastich P. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol. 2017;23(25):4548–4558. doi:10.3748/wjg.v23.i25.4548. PMID: 28740343.
   PubMed Web of Science ®Google Scholar
• Alipour M, Zaidi D, Valcheva R, Jovel J, Martinez I, Sergi C, Walter J, Mason AL, Wong GK, Dieleman LA, et al. Mucosal barrier depletion and loss of bacterial diversity are primary abnormalities in paediatric ulcerative colitis. J Crohns Colitis. 2016;10(4):462–471. doi:10.1093/ecco-jcc/jiv223. PMID: 26660940.
   PubMed Web of Science ®Google Scholar
• Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79. doi:10.1186/gb-2012-13-9-r79. PMID: 23013615.
   PubMed Web of Science ®Google Scholar
• Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn´s disease involving the ileum. Isme J. 2007;1(5):403–418. doi:10.1038/ismej.2007.52. PMID: 18043660.
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, et al. The treatment-naïve microbioma in new-onset Crohn´s disease. Cell Host Microbe. 2014;15(3):382–392. doi:10.1016/j.chom.2014.02.005. PMID: 24629344.
   PubMed Web of Science ®Google Scholar
• Aden K, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, Nunez AM, Bharti R, Zimmerman J, Bethge J, et al. Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel disease. Gastroenterology. 2019;157(5):1279–1292. doi:10.1053/j.gastro.2019.07.025. PMID: 31326413.
   PubMed Web of Science ®Google Scholar
• Nemoto H, Kataoka K, Ishikawa H, Ikata K, Arimochi H, Iwasaki T, Ohnishi Y, Kuwchara T, Yasutomo K. Reduced diversity and imbalanced fecal microbiota in patients with ulcerative colitis. Dig Dis Sci. 2012;57(11):2955–2964. doi:10.1007/s10620-012-2236-y. PMID:22623042.
   PubMed Web of Science ®Google Scholar
• Kabeerdoss J, Jayakanthan P, Pugazhendhi S, Ramakrishna SB. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res. 2015;142(1):23–32. doi:10.4103/0971-5916.162091. PMID: 26261163.
   PubMedGoogle Scholar
• Danilova NA, Abdulkhakov SR, Grigoryeva TV, Markelova MI, Vailyev IY, Boulygina EA, Ardatskaya MD, Pavlenko AV, Tyakht AV, Odintsova AK, et al. Markers of dysbiosis in patients with ulcerative colitis and Crohn´s disease. Ter Arkh. 2019;91(4):17–24. doi:10.26442/00403660.2019.04.000211. PMID: 31094471.
   PubMed Web of Science ®Google Scholar
• Altomare A, Putignani L, Del Chierico F, Cocca S, Angeletti S, Ciccozzi M, Tripiciano C, Dalla Piccola B, Cicala M, Guarino MPL, et al. Gut mucosal-associated microbiota better discloses inflammatory bowel disease differential patterns than faecal microbiota. Dig Liver Dis. 2019;51(5):648–656. doi:10.1016/j.dld.2018.11.021. PMID: 30573380.
   PubMedGoogle Scholar
• Imhann F, Vich Vila A, Bonder MJ, Fu J, Gevers D, Visschedijk MC, Spekhorst LM, Alberts R, Franke L, van Dullemen HM, et al. Interplay of host genetics and gut microbiota underlaying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018;67(1):108–119. doi:10.1136/gutjnl-2016-312135. PMID: 27802154.
   PubMed Web of Science ®Google Scholar
• Shaw KA, Bertha M, Hofmekler T, Chopra P, Vatanen T, Srivatsa A, Prince J, Kumar A, Sauer C, Zwick ME. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med. 2016;8(1):75. doi:10.1186/s13073-016-0331-y. PMID: 27412252.
   PubMedGoogle Scholar
• Andoh A, Kuzuoka H, Tsujikawa T, Nakamura S, Hirai F, Suzuki Y, Matsui T, Fujiyama Y, Matsumoto T. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn´s disease. J Gastroenterol. 2012;47(12):1298–1307. doi:10.007/s00535-012-0605-0. PMID:22576027.
   PubMed Web of Science ®Google Scholar
• Lo Presti A, Zorzi F, Del Chierico F, Altomare A, Cocca S, Avola A, De Biasio F, Russo A, Cella E, Reddel S, et al. Fecal and mucosa microbiota profiling in irritable bowel syndrome and inflammatory bowel disease. Front Microbiol. 2019;10:1655. doi:10.3389/fmicb.2019.01655. PMID: 31379797.
   PubMed Web of Science ®Google Scholar
• Nishino K, Nishida A, Inoue R, Kawada Y, Ohno M, Skai S, Inatomi O, Bamba S, Sugimoto M, Kawahara M, et al. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. J Gastroenterol. 2018;53(1):95–106. doi:10.1007/s00535-017-1384-4. PMID: 28852861.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier L, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, et al. Reduced diversity of faecal microbiota in Crohn´s disease revealed by a metagenomic approach. Gut. 2006;55(2):205–211. doi:10.1136/gut.2005.073817. PMID: 16188921.
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. Proc Natl Acad Sci USA. 2007;104(34):13780–13785. doi:10.1073/pnas.0706625104. PMID: 17699621.
   PubMed Web of Science ®Google Scholar
• Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett. 2002;217(2):133–139. doi:10.1111/J.1574-6968.2002.tb11467.x. PMID: 12480096.
   PubMed Web of Science ®Google Scholar
• Rajca S, Grondin V, Louis E, Venier-Massoville G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn´s disease. Inflamm Bowel Dis. 2014;20(6):978–986. doi:10.1097/MIB.0000000000000036. PMID: 24788220.
   PubMed Web of Science ®Google Scholar
• Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53(5):685–693. doi:10.101136/gut2003.025403. PMID: 15082587.
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Chen EZ, Baldassson RN, Otley AR, Griffiths AN, Lee D, Bithinger K, Bailey A, Friedman ES, Hoffmann C, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn´s disease. Cell Host Microbe. 2015;18(4):489–500. doi:10.1016/j.chom.2015.09.008. PMID:26468751.
   PubMed Web of Science ®Google Scholar
• Halfvarson J, Brislawn CJ, Lamendella R, Vazquez-Baeza Y, Walters WA, Bramer LM, D´Amato M, Bonfiglio F, McDonald D, Gonzalez A, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004. doi:10.1038/nmicrobiol.2017.4. PMID: 28191884.
   PubMed Web of Science ®Google Scholar
• Rojas-Feria M, Romero-García T, Fernández Caballero-Rico JA, Pastor Ramírez H, Avilés-Recio M, Castro-Fernández M, Chueca Porcuna N, Romero-Gómez M, García F, Grande L, et al. Modulation of faecal metagenome in Crohn´s disease: role of microRNAs as biomarkers. World J Gastroenterol. 2018;24(46):5223–5233. doi:10.3748/wjg.v24.i46.5223. PMID: 30581271.
   PubMed Web of Science ®Google Scholar
• Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikama T, Fujiyama Y. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn´s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46(4):479–486. doi:10.1007/s00535-010-0368-4. PMID: 21253779.
   PubMed Web of Science ®Google Scholar
• Knoll RL, Forslund K, Kultima JR, Meyer CU, Kullmer U, Sunagawa S, Bork P, Gehring S. Gut microbiota differs between children with inflammatory bowel disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis. Am J Physiol Gastrointest Liver Physiol. 2017;312(4):G327–G339. doi:10.1152/ajpgi.00293.2016. PMID: 28039159.
   PubMed Web of Science ®Google Scholar
• Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, Mclver LJ, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Natural Microbiol. 2019;4(2):293–305. doi:10.1038/s41564-018-0306-5. PMID: 30531976.
   PubMed Web of Science ®Google Scholar
• Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brisawn CJ, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel disease. Nature. 2019;569(7758):655–662. doi:10.1038/s41586-019-1237-9. PMID: 31142855.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Imaeda H, Takahashi K, Kasumi E, Bamba S, Fujiyama Y, Amdoh A. Decrease abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn´s disease. J Gastroenterol Hepatol. 2013;28(4):613–619. doi:10.1111/jgh.12073. PMID: 23216550.
   PubMed Web of Science ®Google Scholar
• Wright EK, Kamm MA, Wagner J, Teo SM, Cruz P, Hamilton AL, Ritchie KJ, Inouye M, Kirkwood CD. Microbial factors associated with postoperative Crohn´s disease recurrence. J Crohns Colitis. 2017;11(2):191–203. doi:10.1093/ecco-jcc/jjw136. PMID: 27466174.
   PubMed Web of Science ®Google Scholar
• Vaster-Andersen MK, Mirsepasi-Lauridsen HC, Prosberg MV, Mortensen CO, Träger C, Skovsen K, Thorkilgaard T, Nojgaard C, Vind I, Krogfelt KA, et al. Increased abundance of proteobacteria in aggressive Crohn´s disease seven years after diagnosis. Sci Rep. 2019;9(1):13473. doi:10.1038/s41598-019-49833-3. PMID: 31530835.
   PubMedGoogle Scholar
• Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn´s disease and ulcerative colitis can be specifically diagnosis and monitored based on the biostructure of fecal flora. Inflamm Bowel Dis. 2008;14(2):147–161. doi:10.101002/ibd.20330. PMID: 18050295.
   PubMed Web of Science ®Google Scholar
• Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH. Mucolytic bacteria wit increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010;105(11):2420–2428. doi:10.1038/ajg.2010.281. PMID: 20648002.
   PubMed Web of Science ®Google Scholar
• Jacobs JP, Goudarzi M, Singh N, Tong M, McHardy IH, Rvegger P, Asadourian M, Moon B, Ayson A, Borneman Y, et al. A disease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients. Cell Mol Gastroenterol Hepatol. 2016;2(6):750–766. doi:10.1016/j.jcmgh.2016.06.004. PMID: 281747747.
   PubMed Web of Science ®Google Scholar
• Forbes JD, Van Domselaar G, Bernstein CN. Microbiome survey of the inflamed and non-inflamed gut at different compartments within the gastrointestinal tract of inflammatory bowel disease patients. Inflamm Bowel Dis. 2016;22(4):817–825. doi:10.1097/MIB.0000000000000684. PMID: 26937623.
   PubMed Web of Science ®Google Scholar
• Humbel F, Rieder JH, Franc Y, Juillerat P, Scharl M, Misselwitz B, Schreiner P, Begré S, Rogler G, von Känel R, et al. Association of alterations in intestinal microbiota with impaired psychological function in patients with inflammatory bowel disease in remission. Clin Gastroenterol Hepatol. 2019;20. PMID: 31546058. doi:10.1016/j.cgh.2019.09.022.
   Google Scholar
• Lopez-Siles M, Enrich-Capó N, Aldeguer X, Sabat-Mir M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Alterations in the abundance and co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the colonic mucosa of inflammatory bowel disease subjects. Front Cell Infect Microbiol. 2018;8:281. doi:10.3389/fcimb.2018.00281. PMID: 30245977.
   PubMed Web of Science ®Google Scholar
• Ring C, Klopfleisch R, Dahlke K, Basic M, Bleich A, Blaut M. Akkermansia nuciniphila strain ATCC BAA-835 does not promote short-term intestinal inflammation in gnotobiotic interleukin-10-deficient mice. Gut Microbes. 2019;10(2):180–203. doi:10.1080/19490976.2018.1511663. PMID: 30252588.
   Web of Science ®Google Scholar
• Geerlings SY, Kostopoulos I, de Vos WM, Belzer C. Akkermansia. muciniphila in the human gastrointestinal tract: when, where, and how? Microorganisms. 2018;6(3):75. doi:10.3390/microorganisms6030075. PMID: 30041463.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, K V, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275–1283. doi:10.1136/gutjnl-2013-304833. PMID: 24021287.
   PubMed Web of Science ®Google Scholar
• Rajilic-Stojanovic M, Shanahan F, Guarner F, de Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013;19(3):481–488. doi:10.1097/MIB.0b013E31827fec6d. PMID: 23385241.
   PubMed Web of Science ®Google Scholar
• Sokol H, Jegou S, McQuitty C, Straub M, Leducq V, Landman C, Kirchgesner J, Le Gall G, Bourrier A, Nion-Larmurier I, et al. Specificities in the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. Gut Microbes. 2018;9(1):55–60. doi:10.1080/19490976.2017.1361092. PMID: 28786749.
   PubMed Web of Science ®Google Scholar
• Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA. Short chain fatty acids (SCFAs)- mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. doi:10.3389/fimmu.2019.00227. PMID: 30915065.
   PubMed Web of Science ®Google Scholar
• Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619–1625. doi:10.3945/jn.109.104638. PMID:19625695.
   PubMed Web of Science ®Google Scholar
• Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbial. 2013;51(9):2884–2892. doi:10.1128/JCM.00845-13. PMID: 23804381.
   PubMed Web of Science ®Google Scholar
• Wilson BC, Vatanen T, Cutfield WS, O´Sullivan JM. The Super-Donor Phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol. 2019;9:2. doi:10.3389/fcjmb.2019.00002. PMID: 30719428.
   PubMed Web of Science ®Google Scholar
• Kellingray L, Le Gall G, Defernez M, Beales ILP, Franslem-Elumogo N, Narbad A. Microbial taxonomic and metabolic alterations during faecal microbiota transplantation to treat Clostridium difficile infection. J Infect. 2018;77(2):107–118. doi:10.1016/j.jinf.2018.04.012. PMID: 29746938.
   PubMed Web of Science ®Google Scholar
• Collins J, Auchtung JM. Control of Clostridium difficile infection by defined microbial communities. Microbiol Spectr. 2017;5(5). doi:10.1128/microbiolspec.BAD-0009-2016. PMID: 28936948.
   Web of Science ®Google Scholar
• Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational design of combination microbial therapies. Clin Microbiol Rev. 2017;30(1):191–231. doi:10.1128/CMR.00049-16. PMID: 27856521.
   PubMed Web of Science ®Google Scholar
• Shankar V, Hamilton MJ, Khoruts A, Kilburn A, Unno T, Paliy O, Sadowsky MJ. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014;2:13. doi:10.1186/2049-2618-2-13. PMID: 24855561.
   PubMed Web of Science ®Google Scholar
• Amrane S, Hocquart M, Afouda P, Kuete E, Pham TPT, Dione N, Ngom II, Valles C, Banchar D, Raoult D, et al. Metagenomic and culturomic analysis of gut microbiota dysbiosis during Clostridium difficile infection. Sci Rep. 2019;9:12807. doi:10.1038/s41598-019-49189-8. PMID 31488869.
   PubMed Web of Science ®Google Scholar
• Mullish BH, JAK M, Pechlivanis A, Allegratti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM, et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut. 2019;11. PMID: 30816855. doi:10.1136/gutjnl-2018-317842.
   Google Scholar
• Thoma C. Bile salt involved in the effectiveness of FMT for Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2019;16(4):198. doi:10.1038/s41575-019-0128-8. PMID: 30837698.
   Google Scholar
• Hatziioanou D, Gherghisan-Filip C, Saalbach G, Horn N, Wegmann U, Ducan SH, Flint HJ, Mayer MJ, Narbad A. Discovery of a novel lantibiotic nisin O from Blautia obeum A2-162, isolated from the human gastrointestinal tract. Microbiology. 2017;163(9):1292–1305. doi:10.1099/mic.0.000515. PMID: 28857034.
   PubMed Web of Science ®Google Scholar
• Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1(8648):1156. doi:10.1016/s0140-6736(89)92749-9. PMID: 2566734.
   PubMed Web of Science ®Google Scholar
• Bäumer AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016;535(7610):85–93. doi:10.1038/nature18849. PMID: 27383983.
   PubMed Web of Science ®Google Scholar
• Ng SC, Kamm MA, Yeoh YK, Chan PKS, Zuo T, Tang W, Sood A, Andoh A, Ohmiya N, Zhou Y, et al. Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific association of gastroenterology (APAGE) and Asia-Pacific Society for digestive endoscopy (APSDE). Gut. 2019;14. PMID: 31611298. doi:10.1136/gutjnl-2019-319407.
   Google Scholar
• Mirpuri J, Raetz M, Sturge CR, Wilhelm CL, Benson A, Savani RC, Hooper LV, Yarovinsky F. Proteobacteria-specific IgA regulates maturation of the intestinal microbiota. Gut Microb. 2014;5(1):28–39. doi:10.4161/gmic.26489. PMID: 24637807.
   PubMed Web of Science ®Google Scholar
• Ross CL, Spinter JK, Savidge TC. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Anaerobe. 2016;41:37–43. doi:10.1016/j.anaerobe.2016.05.006. PMID: 2718006.
   PubMed Web of Science ®Google Scholar
• Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14(10):573–584. doi:10.1038/nrgastro.2017.88. PMID: 28743984.
   PubMed Web of Science ®Google Scholar
• Pitts AC, Tuck LR, Faulds-Pain A, Lewis RJ, Marles-Wright J. Structural insight into the Clostridium difficile ethanolamine utilisation microcompartment. PLoS One. 2012;7(10):e48360. doi:10.1371/journal.pone.0048360. PMID: 23144756.
   PubMed Web of Science ®Google Scholar
• Stecher B. The roles of inflammation, nutrient availability and the commensal microbiota in enteric pathogen infection. Microbial Spectr. 2015;3(3). doi:10.1128/microbiolspec.MBP-0008-2014. PMID: 26185088.
   PubMed Web of Science ®Google Scholar
• Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, Naidu N, Choudhury B, Weimer BC, Monack DM, et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature. 2013;502(7469):96–99. doi:10.1038/nature12503. PMID: 23995682.
   PubMed Web of Science ®Google Scholar
• Passmore IJ, Letertre MPM, Preston MD, Bianconi I, Harrison MA, Nasher F, Kaur H, Hong HA, Baines SD, Cutting SM, et al. Paracresol production by Clostridium difficile affects microbial diversity and membrane interplay of Gram-negative bacteria. PLoS One. 2018;14(9):e1007191. doi:10.1371/journal.ppat.1007191. PMID: 30208103.
   Google Scholar
• Vidal-Lletjós S, Beaumont M, Torné D, Benamouzig R, Blachier F, Lan A. Dietary protein and amino acid supplementation in inflammatory bowel disease course: what impact on the colonic mucosa? Nutrients. 2017;9(3):310. doi:10.3390/nu9030310. PMID: 28335546.
   Web of Science ®Google Scholar
• Hellmann J, Andersen H, Fei L, Linn A, Bezold R, Lake K, Jackson K, Meyer D, Dirksing K, Bonkowski E, et al. Microbial shifts and shorter time to bowel resection surgery associated with C. difficile in pediatric Crohn´s disease. Inflamm Bowel Dis. 2019;14. PMID 31725875. doi:10.1093/ibd/izz263.
   Google Scholar
• Crost EH, Tailford LE, Le Gall G, Fons M, Henrissat B, Juge N. Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus ls strain-dependent. PLoS One. 2013;8(10):e76341. doi:10.1371/journal.pone.0076341. PMID: 24204617.
   PubMed Web of Science ®Google Scholar
• Milani C, Ticinesi A, Gerritsen J, Nouvenne A, Lugli GA, Mancabelli L, Turroni F, Duranti S, Mangifecta M, Viappiani A, et al. Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci Rep. 2016;6:25945. doi:10.1038/srep25945. PMID:27166072.
   PubMed Web of Science ®Google Scholar
• Shin JH, Gao Y, II JH M, Bolick DT, Kolling GL, Wu M, Warren CA. Innate Immune response and outcome of Clostridium difficile infection are dependent on fecal bacterial composition in the aged host. J Infect Dis. 2018;217(2):188–197. doi:10.1093/infdis/jix414. PMID:28968660.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013;4(2):125–135. doi:10.4161/gmic.23571. PMID: 23333862.
   PubMed Web of Science ®Google Scholar
• Zhang X, Deeke SA, Ning Z, Starr AE, Butcher J, Li J, Mayne J, Cheng K, Liao B, Li L, et al. Metaproteomics reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. Nat Commun. 2018;9:2873. doi:10.1038/s41467-018-05357-4. PMID: 30030445.
   PubMed Web of Science ®Google Scholar
• Cascio V, Gittings D, Merloni K, Hurton M, Laprade D, Austriaco N. S-Adenpsyl-L. Methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death. BMC Microbiol. 2013;13:35. doi:10.1186/1471-2180-13-35. PMID: 23402325.
   PubMed Web of Science ®Google Scholar
• Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn´s disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135(3):490–496. doi:10.1111/j.1365-2249.2003.02392.x. PMID: 15008984.
   PubMed Web of Science ®Google Scholar
• Levy AN, Allegretti JR. Insights into the role of transplantation for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol. 2019;12. doi:10.1177/1756284819836893. PMID: 24241245.
   PubMed Web of Science ®Google Scholar
• Fisher M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2402–2409. doi:10.1097/MIB0000000000000908. PMID: 27580384.
   PubMed Web of Science ®Google Scholar
• Chin SM, Sauk J, Mahabamunuge J, Kaplan JL, Hohmann EL, Khalili H. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: a single center experience. Clin Gastroenterol Hepatol. 2017;15(4):597–599. doi:10.1016/j.cgh.2016.11.028. PMID: 27923723.
   PubMed Web of Science ®Google Scholar
• Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, Sadowsky MJ. Inflammatory Bowel Disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14(10):1433–1438. doi:10.1016/j.cgh.2016.02.018. PMID: 26905904.
   PubMed Web of Science ®Google Scholar
• Meighani A, Hart BR, Bourgi K, Miller N, John A, Ramesh M. Outcome of fecal microbiota transplantation for Clostridium difficile infection in patients with IBD. Dig Dis Sci. 2017;62(10):2870–2875. doi:10.1007/s10620-017-4580-4. PMID: 28451916.
   PubMed Web of Science ®Google Scholar
• Kahn S, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on FMT 2015: indications, methodologies, mechanisms and outlook. Gastroenterology. 2016;159(1):223–237. doi:10.1053/j.gastro.2015.05.008. PMID: 25982290.
   Google Scholar
• Wang B, Zhang L, Zhu SW, Zhang JD, Duan LP. Short chain fatty acids contribute to gut microbiota-induced promotion of colonic melatonin receptor expression. J Biol Regul Homeost Agents. 2019;33(3):763–771. PMID:31204469.
   PubMed Web of Science ®Google Scholar
• Ling Z, Liu X, Jia X, Cheng Y, Luo Y, Yuan L, Wang Y, Zhao C, Guo S, Li L, et al. Impacts of infection with different toxigenic Clostridium difficile strains on feacal microbiota. Sci Rep. 2014;4:7485. doi:10.1038/srep07485. PMID: 25501371.
   PubMed Web of Science ®Google Scholar
• Li N, Tian H. Current research progress and thinking of fecal microbiota transplantation for the treatment of gastrointestinal disorders. Zhunghua Wei Chang Ke Za ZHi. 2017;20(10):1104–1108. PMID:29130220.
   PubMedGoogle Scholar
• Qazi T, Amaratunga T, Barnes EL, Fisher M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis. Gut Microbes. 2017;8(6):574–588. doi:10.1080/19490976.2017.1353848. PMID: 28723262.
   PubMed Web of Science ®Google Scholar
• Terveer EM, van Gool T, Ooijevaar RE, Sanders IMJG, Boeije-Koppenol E, Keller JJ, Bart A, Kuijper EJ, Terveer EM, Vendrik K, et al. Human transmission of Blastocystis by fecal microbiota transplantation without development of gastrointestinal symptoms in recipients. Clin Infect Dis. 2019;15. PMID: 31728525. doi:10.1093/cid/ciz1122.
   Google Scholar
• Zhang T, Lu G, Zhao Z, Liu Y, Shen Q, Li P, Chen Y, Yin H, Wang H, Marcella C, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. Protein Cell. 2020;9. PMID: 31919742. doi:10.1007/s13238-019-00684-8.
   Google Scholar
• Bassos PJ, NOS C, Sales-Campos H. Microbial-based therapies in the treatment of inflammatory bowel disease- an overview of human studies. Front Pharmacol. 2019;9:1571. doi:10.3389/fphar.2018.01571. PMID: 30687107.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu M, Zhou J, Hou B, Su X, Liu Z, Yuan J, Li M. Bacillus licheniformis Zhengchangsheng attenuates DSS-induced colitis and modulates the gut microbiota in mice. Benef Microbes. 2019;10(5):543–553. doi:10.3920/BM2018.0122. PMID: 31122042.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Sission G, Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology. 2019;27(3):446–473. doi:10.1007/s10787-019-00595-4. PMID: 31054010.
   Web of Science ®Google Scholar
• Nagamine T, Matsumoto Y, Nakamura M. Combination probiotics may prevent Clostridium difficile infection among elderly patients undergoing an orthopedic surgery. Biosci Microbiota Food Health. 2019;38(1):31–33. doi:10.12938/bmfh.18-009. PMID: 30705800.
   PubMed Web of Science ®Google Scholar
• Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol. 2018;34(1):3–10. doi:10.1097/MOG.0000000000000410. PMID: 29189354.
   PubMed Web of Science ®Google Scholar
• Dai D, Wang T, Wu S, Gao NL, Chen WH. Metabolic dependencies underlie interaction patterns of gut microbiota during enteropathogenesis. Front Microbiol. 2019;10:1205. doi:10.3389/fmicb.2019.01205. PMID: 31214144.
   PubMed Web of Science ®Google Scholar